Factors associated with interest in initiating treatment for hepatitis C virus (HCV) infection among young HCV-infected injection drug users

被引:95
作者
Strathdee, SA
Latka, M
Campbell, J
O'Driscoll, PT
Golub, ET
Kapadia, F
Pollini, RA
Garfein, RS
Thomas, DL
Hagan, H
机构
[1] Univ Calif San Diego, Dept Family & Prevent Med, Div Int Hlth & Cross Cultural Med, La Jolla, CA 92093 USA
[2] New York Acad Med, Ctr Urban Epidemiol Studies, New York, NY USA
[3] Ctr Drug Use & HIV Res, Natl Dev & Res Inst, New York, NY USA
[4] Seattle King Cty Dept Publ Hlth, Epidemiol Res Unit, Seattle, WA USA
[5] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[6] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA
[7] Ctr Dis Control & Prevent, Natl Ctr HIV STD & TB Prevent, Div HIV AIDS Prevent, Atlanta, GA USA
关键词
D O I
10.1086/427445
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective. We sought to identify factors associated with interest in receiving therapy for hepatitis C virus (HCV) infection among HCV-infected injection drug users (IDUs) in 3 United States cities. Methods. IDUs aged 18 - 35 years who were HCV-infected and seronegative for human immunodeficiency virus underwent surveys on behaviors, experience, and interest in treatment for HCV infection and readiness to quit drug use. Results. Among treatment-naive IDUs (n = 216), 81.5% were interested in treatment for HCV infection, but only 27.3% had seen a health-care provider since receiving a diagnosis of HCV infection. Interest in treatment for HCV infection was greater among IDUs with a high perceived threat of progressive liver disease, those with a usual source of care, those without evidence of alcohol dependence, and those with higher readiness scores for quitting drug use. Interest in treatment for HCV infection was 7-fold higher among IDUs who were told by their health-care provider that they were at risk for cirrhosis or liver cancer. Conclusions. Improving provider-patient communication and integrating treatments for substance abuse and HCV may increase the proportion of IDUs who initiate treatment for HCV infection.
引用
收藏
页码:S304 / S312
页数:9
相关论文
共 39 条
[1]  
Altice FL, 2001, J ACQ IMMUN DEF SYND, V28, P47, DOI 10.1097/00042560-200109010-00008
[2]  
[Anonymous], 1997, NIH Consens Statement, V15, P1
[3]  
[Anonymous], 2002, NIH Consens State Sci Statements, V19, P1
[4]   Treatment of hepatitis C infection in injection drug users [J].
Backmund, M ;
Meyer, K ;
Von Zielonka, M ;
Eichenlaub, D .
HEPATOLOGY, 2001, 34 (01) :188-193
[5]   STAGES AND PROCESSES OF CHANGE AMONG POLYDRUG USERS IN METHADONE-MAINTENANCE TREATMENT [J].
BELDING, MA ;
IGUCHI, MY ;
LAMB, RJ ;
LAKIN, M ;
TERRY, R .
DRUG AND ALCOHOL DEPENDENCE, 1995, 39 (01) :45-53
[6]  
Booth R E, 1998, Public Health Rep, V113 Suppl 1, P116
[7]   Dual diagnosis: A treatment model for substance abuse and major mental illness [J].
Brady, S ;
Hiam, CM ;
Saemann, R ;
Humbert, L ;
Fleming, MZ ;
DawkinsBrickhouse, K .
COMMUNITY MENTAL HEALTH JOURNAL, 1996, 32 (06) :573-578
[8]   Self-reported antiretroviral therapy in injection drug users [J].
Celentano, DD ;
Vlahov, D ;
Cohn, S ;
Shadle, VM ;
Obasanjo, O ;
Moore, RD .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (06) :544-546
[9]  
Coulon M, 2003, PRESSE MED, V32, P1642
[10]   Epidemiology of hepatitis C virus infection in Australia [J].
Dore, GJ ;
Law, M ;
MacDonald, M ;
Kaldor, JM .
JOURNAL OF CLINICAL VIROLOGY, 2003, 26 (02) :171-184